
Opinion|Videos|April 22, 2025
What Lies Ahead for GPP Diagnosis and Management
Panelists discuss how the future of generalized pustular psoriasis (GPP) diagnosis and management looks promising with emerging genetic testing for IL36RN mutations, development of multiple targeted biologics beyond IL-36 inhibitors, potential personalized treatment algorithms, improved disease classification, and enhanced multidisciplinary care approaches to better address this rare but severe dermatological condition.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Expanding Oral JAK Inhibitor Options for Children With AD and Alopecia Areata
3
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
4
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
5












